<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="42"><SearchResults><Trial Id="86279"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Synergist</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Natural product</Technology><Technology>Pharmaceutical carrier</Technology><Technology>Protein conjugated</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company></CompaniesSponsor><Countries><Country>Pakistan</Country><Country>Portugal</Country><Country>Hungary</Country><Country>Germany</Country><Country>Uruguay</Country><Country>Vietnam</Country><Country>Ukraine</Country><Country>Hong Kong</Country><Country>Turkey</Country><Country>South Africa</Country><Country>Brazil</Country><Country>Thailand</Country><Country>Asia</Country><Country>Venezuela</Country><Country>Costa Rica</Country><Country>South America</Country><Country>France</Country><Country>Lithuania</Country><Country>United Arab Emirates</Country><Country>Algeria</Country><Country>Saudi Arabia</Country><Country>Italy</Country><Country>Spain</Country><Country>Israel</Country><Country>Sweden</Country><Country>Morocco</Country><Country>Kuwait</Country><Country>Peru</Country><Country>UK</Country><Country>China</Country><Country>Australia</Country><Country>Lebanon</Country><Country>Colombia</Country><Country>Belgium</Country><Country>Greece</Country><Country>Singapore</Country><Country>Qatar</Country><Country>Japan</Country><Country>Poland</Country><Country>Austria</Country><Country>Finland</Country><Country>Philippines</Country><Country>Argentina</Country><Country>Egypt</Country><Country>Chile</Country><Country>Mexico</Country><Country>India</Country><Country>Russian Federation</Country><Country>Europe</Country><Country>Netherlands</Country><Country>Serbia</Country><Country>Ecuador</Country><Country>Slovenia</Country><Country>Canada</Country><Country>Indonesia</Country><Country>Bahrain</Country><Country>Estonia</Country><Country>Africa</Country></Countries><DateChangeLast>2019-05-24T00:00:00Z</DateChangeLast><DateEnd>2019-09-28T00:00:00Z</DateEnd><DateStart>2012-06-01T00:00:00Z</DateStart><Identifiers><Identifier>11574</Identifier><Identifier>2011-005334-20</Identifier><Identifier>CTR20130952</Identifier><Identifier>JXSL1200006</Identifier><Identifier>MO28047</Identifier><Identifier>NCT01572038</Identifier><Identifier>PERUSE</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Alopecia</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Dysgeusia</Indication><Indication>Dyspnea</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Epistaxis</Indication><Indication>Erythema</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hypersensitivity</Indication><Indication>Metastatic CNS cancer</Indication><Indication>Myalgia</Indication><Indication>Nail disease</Indication><Indication>Nausea</Indication><Indication>Neurotoxicity drug-induced</Indication><Indication>Neutropenia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including docetaxel , docetaxel + paclitaxel + Abraxane , paclitaxel , paclitaxel (albumin-bound nanoparticle, intravenous), Celgene , pertuzumab , trastuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1436</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This multicenter, open-label, single-arm, Phase IIIb study was to evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane in first-line treatment in patients with metastatic or locally recurrent HER2-positive breast cancer [ 1562342 ]. Main objective of the trial was to evaluate the safety and tolerability of pertuzumab in combination with trastuzumab and a taxane. Secondary objectives of the trial were: To evaluate pertuzumab in combination</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of time to tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT - Breast Cancer (FACT-B)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ejection fraction </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>87 Months</TrialDuration><NumberOfSites>753</NumberOfSites><ContactNames><Name>Clinical Operations</Name><Name>Clinical Trials</Name><Name>David Miles</Name><Name>HU Xi-chun</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="86076"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Hyaluronidase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drug combination</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Recombinant enzyme</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>ROCHE (MALAYSIA) SDN. BHD</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Greece</Country><Country>UK</Country><Country>France</Country><Country>Spain</Country><Country>Colombia</Country><Country>Ecuador</Country><Country>Pakistan</Country><Country>Slovenia</Country><Country>Trinidad and Tobago</Country><Country>Tunisia</Country><Country>Venezuela</Country><Country>Bahrain</Country><Country>Albania</Country><Country>Australia</Country><Country>Argentina</Country><Country>Panama</Country><Country>Sweden</Country><Country>Ukraine</Country><Country>Germany</Country><Country>South Korea</Country><Country>Brazil</Country><Country>Philippines</Country><Country>Dominican Republic</Country><Country>Mexico</Country><Country>El Salvador</Country><Country>Norway</Country><Country>Lithuania</Country><Country>Montenegro</Country><Country>Bulgaria</Country><Country>Uruguay</Country><Country>Lebanon</Country><Country>Peru</Country><Country>Finland</Country><Country>Taiwan</Country><Country>Turkey</Country><Country>Netherlands</Country><Country>United Arab Emirates</Country><Country>Switzerland</Country><Country>Egypt</Country><Country>Thailand</Country><Country>Europe</Country><Country>Vietnam</Country><Country>India</Country><Country>Hungary</Country><Country>Portugal</Country><Country>Malaysia</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Kuwait</Country><Country>Indonesia</Country><Country>Qatar</Country><Country>Croatia</Country><Country>Moldova, Republic of</Country><Country>Singapore</Country><Country>Italy</Country><Country>Canada</Country><Country>Guatemala</Country><Country>Algeria</Country><Country>Hong Kong</Country><Country>Serbia</Country><Country>New Zealand</Country><Country>Ireland</Country><Country>South Africa</Country><Country>Slovakia</Country><Country>Romania</Country><Country>Chile</Country><Country>Bosnia and Herzegovina</Country><Country>Morocco</Country><Country>Saudi Arabia</Country></Countries><DateChangeLast>2019-06-11T00:00:00Z</DateChangeLast><DateEnd>2020-03-03T00:00:00Z</DateEnd><DateStart>2012-05-17T00:00:00Z</DateStart><Identifiers><Identifier>10569</Identifier><Identifier>2011-005328-17</Identifier><Identifier>DRKS00004499</Identifier><Identifier>MO28048</Identifier><Identifier>MO28048 10569</Identifier><Identifier>NCT01566721</Identifier><Identifier>NMRR-11-1020-10569</Identifier><Identifier>SafeHER</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Congestive heart failure</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Heart disease</Indication><Indication>Myalgia</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2577</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This multicenter, two-cohort, non-randomized, open-label study would evaluate the safety and tolerability of assisted and self-administered Herceptin SC as adjuvant therapy in patients with early HER2-positive breast cancer following tumor excision. Anticipated time on study treatment was up to one year [ 1496860 ]. Main objective of the trial was: to assess the overall safety and tolerability of Herceptin SC in HER2-positive early breast cancer (EBC) patients with assisted administration using a</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SafeHER: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>93 Months</TrialDuration><NumberOfSites>1032</NumberOfSites><ContactNames><Name>Beena Devi CR</Name><Name>Clinical Trials</Name><Name>Dr Flora Chong Li Tze</Name><Name>Dr LEE WEI CHING</Name><Name>Dr Teoh Choon Yu</Name><Name>Dr. Beena Devi.C.R</Name><Name>Ethics &amp; Administrative Trial Unit</Name><Name>Ms Cheong Jin Ni</Name><Name>Raymond Ng Chee Hui</Name><Name>Sheikh Mohammad Norhafiz Bin Abdul Aziz</Name><Name>Stephen Suresh A/L Santiago George</Name><Name>Ter Yow Wei</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="80762"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Asociacion para el Progreso de la Oncologia en Malaga</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-20T00:00:00Z</DateChangeLast><DateEnd>2011-09-01T00:00:00Z</DateEnd><DateStart>2009-09-30T00:00:00Z</DateStart><Identifiers><Identifier>LongHer</Identifier><Identifier>LongHer</Identifier><Identifier>NCT01433926</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>trastuzumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to analyze the clinical and biological characteristics of patients with disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete remission, partial or stable disease for a period exceeding three years. In addition, there would be a sub-genetic analysis of patients in whom there is availability of a sample of primary tumor preserved in paraffin. The secondary objectives were to: Determine the frequency of patients achieving partial</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LongHer: Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than Three Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Emilio Alba</Name></ContactNames></Trial><Trial Id="77598"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-20T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>ML25493</Identifier><Identifier>NCT01358942</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>156</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This prospective, observational study would evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small-cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without bevacizumab . Data would be collected from each patient at baseline and after four to six cycles of chemotherapy.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms - Symptom assessment by lung cancer symptom scale (LCSS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small-Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>38</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="76940"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-12-14T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ML25494</Identifier><Identifier>NCT01343914</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This retrospective, observational study analyzed demographical, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached &gt;/= 9 months of progression-free survival after Avastin ( bevacizumab )-based first-line therapy. Data was collected for approximately 9 months.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study on Patients With Non-Squamous, Non-Small Cell Lung Cancer Who Reached A Long Progression Free Survival After Avastin (Bevacizumab)-Based First-Line Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>35</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="66319"><Indications><Indication>Bipolar I disorder</Indication><Indication>Depression</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Dopamine transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Psychostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cephalon Inc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>Finland</Country><Country>India</Country><Country>Germany</Country><Country>South Africa</Country><Country>Czech Republic</Country><Country>Ukraine</Country><Country>Spain</Country><Country>Croatia</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Slovakia</Country><Country>Serbia</Country><Country>Poland</Country><Country>France</Country><Country>Argentina</Country><Country>Italy</Country><Country>Bulgaria</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2010-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016648-38</Identifier><Identifier>C10953/3074</Identifier><Identifier>NCT01121536</Identifier><Identifier>SACT_1219</Identifier></Identifiers><IndicationsAdverse><Indication>Akathesia</Indication><Indication>Anxiety disorder</Indication><Indication>Drowsiness</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>armodafinil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>867</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to evaluate the safety and tolerability of long-term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipolar I disorder whose most recent episode was a depressive episode. Secondary objectives of the trial were as follows: To evaluate long-term efficacy of armodafinil treatment as adjunctive therapy for adults who are experiencing a major depressive episode associated with bipolar I disorder, as assessed</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Anxiety by Protocol Specified Scales - Assessment by Hamilton Anxiety Rating Scale (HAM-A)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Quick Inventory Depressive Symptoms (QIDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>292</NumberOfSites><ContactNames><Name>Margui Chia</Name><Name>Sponsor's Medical Expert</Name></ContactNames></Trial><Trial Id="64395"><Indications><Indication>Bipolar I disorder</Indication><Indication>Major depressive disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Dopamine transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Psychostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cephalon Inc</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>France</Country><Country>Poland</Country><Country>Canada</Country><Country>Serbia</Country><Country>Spain</Country><Country>Australia</Country><Country>Argentina</Country><Country>US</Country><Country>Ukraine</Country><Country>Romania</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-016667-11</Identifier><Identifier>C10953/3071</Identifier><Identifier>NCT01072929</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Suicidal ideation</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>armodafinil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>433</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to determine whether armodafinil treatment, at dosages of 150 and 200 mg/day, was more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adult subjects with major depression associated with bipolar I disorder. The main objective of the study was to determine whether armodafinil treatment, at a dosage of 150mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>105</NumberOfSites><ContactNames><Name>Sponsor's Medical Expert</Name></ContactNames></Trial><Trial Id="58318"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company></CompaniesSponsor><Countries><Country>China</Country><Country>France</Country><Country>Spain</Country><Country>Egypt</Country><Country>Brazil</Country><Country>India</Country><Country>Hong Kong</Country><Country>Italy</Country><Country>Saudi Arabia</Country><Country>Turkey</Country><Country>Poland</Country></Countries><DateChangeLast>2017-07-07T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-006872-31</Identifier><Identifier>CTR20131087</Identifier><Identifier>CTRI/2009/091/000423</Identifier><Identifier>IMELDA</Identifier><Identifier>MO22223</Identifier><Identifier>NCT00929240</Identifier></Identifiers><IndicationsAdverse><Indication>Gastroenteritis</Indication><Indication>Hypertension</Indication><Indication>Proteinuria</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>bevacizumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Xeloda + Avastin , bevacizumab , capecitabine , docetaxel</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>287</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This randomized study was to compare maintenance therapy with Avastin (bevacizumab) plus Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel plus Avastin [ 1494889 ]. The study was to assess whether adding Xeloda to maintenance Avastin continued until disease progression (PD) after initial Avastin plus Xeloda improves progression-free survival (PFS) [ 1596254 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IMELDA: A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine) as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>67</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>Jiang Zefei</Name><Name>Li Jing</Name></ContactNames></Trial><Trial Id="56228"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Arnau de Vilanova</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2009-05-27T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ML25033</Identifier><Identifier>NCT00908336</Identifier></Identifiers><InterventionsControlDisplay><Intervention>erlotinib alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>docetaxel plus erlotinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This study will investigate if the intermittent treatment of a chemotherapy drug, such as docetaxel , with erlotinib could achieve a clinical benefit.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 6 months</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicities (Upper and Lower)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Survival - Assessment of median survival</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Unresectable/In-operable Lung Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Alfredo Sánchez, Doctor</Name><Name>Alfreso Sánchez, Doctor</Name><Name>Antonio López, Doctor</Name><Name>Francisco Aparisi, Doctor</Name><Name>Gaspar Esquerdo, Doctor</Name><Name>José Muñoz, Doctor</Name><Name>Oscar Juan, Doctor</Name><Name>Sonia Maciá, Doctor</Name><Name>Vicente Alberola, Doctor</Name><Name>Vicente Giner, Doctor</Name></ContactNames></Trial><Trial Id="55959"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Arnau de Vilanova Hospital</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2009-05-25T00:00:00Z</DateChangeLast><DateEnd>2011-10-31T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>CPNM-PS2-07</Identifier><Identifier>NCT00906061</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>docetaxel plus gemcitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>76</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this phase II study is to evaluate the safetya nd efficacy of biweekly gemcitabine and docetaxel as first line therapy for advanced non-small-cell lung cancer patients with ECOG PS 2.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicities (Upper and Lower)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of hematological toxicities</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of pulmonary toxicities</EndpointIndex><EndpointIndex>Lung tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2009-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Alfredo Sanchez, Doctor</Name><Name>Alfredo Sánchez, Doctor</Name><Name>Alfreso Sánchez, Doctor</Name><Name>Antonio López, Doctor</Name><Name>Francisco Aparisi, Doctor</Name><Name>Gaspar Esquerdo, Doctor</Name><Name>José Gomez, Doctor</Name><Name>José Gómez, Doctor</Name><Name>José Muñoz, Doctor</Name><Name>José muñoz, Doctor</Name><Name>Juan L. Martí, Doctor</Name><Name>Miguel A. Muñoz, Doctor</Name><Name>Oscar Juan, Doctor</Name><Name>Siliva Catot, Doctor</Name><Name>Silvia Catot, Doctor</Name><Name>Sonia Maciá, Doctor</Name><Name>Vicente Alberola, Doctor</Name><Name>Vicente Giner, Doctor</Name><Name>Vicente Marco, Doctor</Name></ContactNames></Trial></SearchResults></trialResultsOutput>